Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS   US4643301090

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/23/2015 01/26/2015 01/27/2015 01/28/2015 01/29/2015 Date
71.28(c) 72.9(c) 72.4(c) 68.58(c) 69.86(c) Last
1 495 785 2 016 646 1 665 443 2 633 442 2 372 190 Volume
+0.42% +2.27% -0.69% -5.28% +1.87% Change
More quotes
Company
Isis Pharmaceuticals, Inc. engages in the development and commercialization of drugs to treat various health conditions, including inflammatory, viral, metabolic and cardiovascular and dermatological diseases and cancer.The company operates in two segments: Drug Discovery & Development and... 
Sector
Biotechnology & Medical Research
Calendar
02/11 | 08:50amPresentation
More about the company
Surperformance© ratings of ISIS Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 200 M
EBIT 2014 -51,4 M
Net income 2014 -61,4 M
Finance 2014 706 M
Yield 2014 -
Sales 2015 182 M
EBIT 2015 -108 M
Net income 2015 -130 M
Finance 2015 657 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 37,7x
EV / Sales 2015 41,8x
Capitalization 8 253 M
More Financials
Latest news on ISIS PHARMACEUTICALS, INC.
01/23 ISIS PHARMACEUTICALS : Alnylam and Isis Form New Agreement, Extending Decade-Lon..
01/15 INSIGHT : Big Pharma faces up to new price pressure from aggressive insurers
01/14 ISIS PHARMACEUTICALS : Studies from ISIS Update Current Data on Antisense Techno..
01/14 ISIS PHARMACEUTICALS : to Present at the 33rd Annual J.P. Morgan Healthcare Conf..
01/14 ISIS PHARMACEUTICALS : Announces Collaboration With Janssen to Discover and Deve..
01/14 INTERLEUKIN GENETICS : Announces Collaboration with Isis Pharmaceuticals for Gen..
01/14 ISIS PHARMACEUTICALS : Earns $7M for Advancing ISIS-SMN Rx in Children With Spin..
01/12 ISIS PHARMACEUTICALS : Alnylam, Isis form new agreement in RNA Therapeutics
More news
Sector news Biotechnology & Medical Research - NEC
01/29DJValeant to Buy Prostate-Cancer Drug From Dendreon
01/29DJValeant in Deal to Buy Prostate-Cancer Drug Provenge From Dendreon
01/29 ALNYLAM PHARMACEUTICALS : Thursday 1/29 Insider Buying Report: ALNY, SSB
Plus d'actualités du secteur Biotechnology & Medical Research - NEC
4-Traders Strategies on ISIS PHARMACEUTICALS, INC. 
2014A resistance as obstacle
More Strategies


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF